| Emem Williams, | |
|
12724 Gran Bay Pkwy W Ste 410, Jacksonville, FL 32258-9486 | |
| (608) 371-9624 | |
| (239) 232-6100 |
| Full Name | Emem Williams |
|---|---|
| Gender | Female |
| Speciality | Social Worker - Clinical |
| Location | 12724 Gran Bay Pkwy W Ste 410, Jacksonville, Florida |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013377365 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1041C0700X | Social Worker - Clinical | CSW005698 (Georgia) | Secondary |
| 1041C0700X | Social Worker - Clinical | SW16586 (Florida) | Primary |
| Entity Name | Mental Health Center Of Florida Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679021414 PECOS PAC ID: 9931485117 Enrollment ID: O20170425000910 |
News Archive
The Center for Global Health Policy's "Science Speaks" blog describes a Capitol Hill briefing that was held Wednesday "to discuss the various evidence-based approaches to prevent HIV infection that the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) program is implementing on the ground in the countries hardest hit by the AIDS pandemic."
The Democrats, and one independent, want to modify a health law provision requiring companies to provide coverage if they have more than 50 employees. The senators want to make the cutoff 100 workers. Other proposals include offering consumers additional health plan choices, among them, a less-expensive "copper" option.
BioMarker Strategies announced today that the National Cancer Institute (NCI) has approved the first $1 million in Phase II funding for the company's Small Business Innovative Research (SBIR) contract to develop the SnapPath™ live tumor cell testing system. The company is developing the SnapPath™ system to better enable drug companies to stratify patients in clinical trials, as well as assist oncologists in determining the most effective targeted drug treatment for their cancer patients.
BioTime, Inc., a biotechnology company that develops and markets products in the field of stem cells and regenerative medicine, today announced it has signed a definitive agreement to merge Utah-based Glycosan BioSystems, Inc. (Glycosan) with BioTime's wholly-owned subsidiary, OrthoCyte Corporation. The acquisition is expected to close by March 18, 2011.
For patients receiving kidney transplants, treatment with cholesterol-lowering "statin" drugs may lead to longer survival, reports a study in the November 2008 Journal of the American Society of Nephrology (JASN).
› Verified 4 days ago
| Entity Name | Transformative Healthcare Solutions Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477114031 PECOS PAC ID: 8921337973 Enrollment ID: O20190917001257 |
News Archive
The Center for Global Health Policy's "Science Speaks" blog describes a Capitol Hill briefing that was held Wednesday "to discuss the various evidence-based approaches to prevent HIV infection that the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) program is implementing on the ground in the countries hardest hit by the AIDS pandemic."
The Democrats, and one independent, want to modify a health law provision requiring companies to provide coverage if they have more than 50 employees. The senators want to make the cutoff 100 workers. Other proposals include offering consumers additional health plan choices, among them, a less-expensive "copper" option.
BioMarker Strategies announced today that the National Cancer Institute (NCI) has approved the first $1 million in Phase II funding for the company's Small Business Innovative Research (SBIR) contract to develop the SnapPath™ live tumor cell testing system. The company is developing the SnapPath™ system to better enable drug companies to stratify patients in clinical trials, as well as assist oncologists in determining the most effective targeted drug treatment for their cancer patients.
BioTime, Inc., a biotechnology company that develops and markets products in the field of stem cells and regenerative medicine, today announced it has signed a definitive agreement to merge Utah-based Glycosan BioSystems, Inc. (Glycosan) with BioTime's wholly-owned subsidiary, OrthoCyte Corporation. The acquisition is expected to close by March 18, 2011.
For patients receiving kidney transplants, treatment with cholesterol-lowering "statin" drugs may lead to longer survival, reports a study in the November 2008 Journal of the American Society of Nephrology (JASN).
› Verified 4 days ago
| Entity Name | Living In Hope Counseling, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356797567 PECOS PAC ID: 5496048449 Enrollment ID: O20240216003781 |
News Archive
The Center for Global Health Policy's "Science Speaks" blog describes a Capitol Hill briefing that was held Wednesday "to discuss the various evidence-based approaches to prevent HIV infection that the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) program is implementing on the ground in the countries hardest hit by the AIDS pandemic."
The Democrats, and one independent, want to modify a health law provision requiring companies to provide coverage if they have more than 50 employees. The senators want to make the cutoff 100 workers. Other proposals include offering consumers additional health plan choices, among them, a less-expensive "copper" option.
BioMarker Strategies announced today that the National Cancer Institute (NCI) has approved the first $1 million in Phase II funding for the company's Small Business Innovative Research (SBIR) contract to develop the SnapPath™ live tumor cell testing system. The company is developing the SnapPath™ system to better enable drug companies to stratify patients in clinical trials, as well as assist oncologists in determining the most effective targeted drug treatment for their cancer patients.
BioTime, Inc., a biotechnology company that develops and markets products in the field of stem cells and regenerative medicine, today announced it has signed a definitive agreement to merge Utah-based Glycosan BioSystems, Inc. (Glycosan) with BioTime's wholly-owned subsidiary, OrthoCyte Corporation. The acquisition is expected to close by March 18, 2011.
For patients receiving kidney transplants, treatment with cholesterol-lowering "statin" drugs may lead to longer survival, reports a study in the November 2008 Journal of the American Society of Nephrology (JASN).
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Emem Williams, 12724 Gran Bay Pkwy W Ste 410, Jacksonville, FL 32258-9486 Ph: (608) 371-9624 | Emem Williams, 12724 Gran Bay Pkwy W Ste 410, Jacksonville, FL 32258-9486 Ph: (608) 371-9624 |
News Archive
The Center for Global Health Policy's "Science Speaks" blog describes a Capitol Hill briefing that was held Wednesday "to discuss the various evidence-based approaches to prevent HIV infection that the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) program is implementing on the ground in the countries hardest hit by the AIDS pandemic."
The Democrats, and one independent, want to modify a health law provision requiring companies to provide coverage if they have more than 50 employees. The senators want to make the cutoff 100 workers. Other proposals include offering consumers additional health plan choices, among them, a less-expensive "copper" option.
BioMarker Strategies announced today that the National Cancer Institute (NCI) has approved the first $1 million in Phase II funding for the company's Small Business Innovative Research (SBIR) contract to develop the SnapPath™ live tumor cell testing system. The company is developing the SnapPath™ system to better enable drug companies to stratify patients in clinical trials, as well as assist oncologists in determining the most effective targeted drug treatment for their cancer patients.
BioTime, Inc., a biotechnology company that develops and markets products in the field of stem cells and regenerative medicine, today announced it has signed a definitive agreement to merge Utah-based Glycosan BioSystems, Inc. (Glycosan) with BioTime's wholly-owned subsidiary, OrthoCyte Corporation. The acquisition is expected to close by March 18, 2011.
For patients receiving kidney transplants, treatment with cholesterol-lowering "statin" drugs may lead to longer survival, reports a study in the November 2008 Journal of the American Society of Nephrology (JASN).
› Verified 4 days ago
Mrs. Amanda Kay Callahan, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 5776 Saint Augustine Rd, Jacksonville, FL 32207 Phone: 904-448-4700 | |
Carol Lynne Miller, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 11812 Valley Garden Dr, Jacksonville, FL 32225 Phone: 904-673-8237 | |
Ms. Latisha M Hill, MSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 4720 Salisbury Rd, Jacksonville, FL 32256 Phone: 904-493-6190 | |
Susan Lee, Clinical Social Worker Medicare: Medicare Enrolled Practice Location: 12086 Ft.caroline Rd Suite 401, Jacksonville, FL 32225 Phone: 904-565-1271 Fax: 904-645-7325 | |
Sarah Johanna Miller, LCSW Clinical Social Worker Medicare: Medicare Enrolled Practice Location: 820 Prudential Dr Ste 510, Jacksonville, FL 32207 Phone: 904-376-3800 | |
Kallyn Richardson, Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 11478 Harlan Dr, Jacksonville, FL 32218 Phone: 734-834-0459 | |
Maria Susan Martinez, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 1760 Edgewood Ave W, Jacksonville, FL 32208 Phone: 904-301-4900 Fax: 904-924-1773 |